KORU Medical Systems, Inc. logo

KORU Medical Systems, Inc.(KRMD)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 3 days
PROFIT SINCE LAST BUY
-4.88% ▼
LAST CLOSE
$3.7
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for KRMD

11/13/2026: KRMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.

KORU Medical Systems is a medical technology company specializing in portable mechanical infusion systems for subcutaneous drug delivery. Its primary strength lies in its established Freedom platform and recurring-use disposable supplies, supported by high patient adherence and expanding pharmaceutical collaborations. The main investment story centers on growth opportunities in international markets and new drug label expansions, counterbalanced by risks from intense competition, pharma bundling, and micro-cap volatility. The stock suits growth-oriented or active investors willing to monitor quarterly profitability trends, regulatory milestones, and execution progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile KORU offers expanding revenue and pipeline opportunities in subcutaneous drug delivery, its small scale and historical micro-cap profile temper pure growth appeal.
Momentum investorStrong fit while signal remains positiveRecent positive earnings inflection and strong short-term price breakouts attract active momentum participants.
Value investorMixed fitValuation multiples remain elevated relative to current earnings maturity, though expanding profitability improves long-term fundamental support.
Dividend investorWeak fitThe company does not pay dividends, directing all capital toward reinvestment and growth.
Low-risk investorWeak fitMicro-cap volatility, customer concentration, and execution risks present higher risk profiles unsuited for conservative capital preservation mandates.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighAs a micro-cap medical technology stock, shares are susceptible to sharp price swings based on quarterly results and sentiment.
Valuation riskMedium / highForward expectations require sustained execution to justify current valuation multiples as profitability scales.
Competition risk (pharma bundling and large device competitors)HighWell-capitalized pharmaceutical and device competitors possess superior resources to bundle rival drug-delivery systems.
Business qualityMediumThe razor-and-blade recurring revenue model provides solid gross margins, but single-product reliance limits broader franchise breadth.
Dividend incomeLow / noneNo dividend is paid, offering zero income return for yield-focused investors.
Execution riskMedium / highSuccessful commercialization of new pipeline drugs and international market expansion depend heavily on flawless operational execution.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 160.49M USD
Price to earnings Ratio -
1Y Target Price 6.12
Price to earnings Ratio -
1Y Target Price 6.12
Volume (30-day avg) 190.2K shares
Beta 0.52
52 Weeks Range 2.86 - 6.61
Updated Date 11/15/2026
52 Weeks Range 2.86 - 6.61
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.02

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Instruments & Supplies

BUY participation
60.0%
Active BUY / eligible
3 / 5
30-Day BUY Count Change
+1

Eligible universe: 5 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 15.7%
Avg. Invested days 27
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 2.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
KRMD receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
KRMD has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+56.5%) and solid revenue growth (+22.2%) are partially offset by weak cash generation (FCF margin -1.1%), weak profitability (net margin -6.4%).

Financial Health Rating

★★★★★
KRMD's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 41.8%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is KRMD's strongest growth driver at +70.9% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+22.2%, solid) and earnings growth (+56.5%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 58.6% and approximately 72.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 8.77% supports management-shareholder alignment.

Top 5 Institutional Investors

First Light Asset Management, LLC 7.34%
Topline Capital Management LLC 7.31%
BlackRock Inc 5.69%
Vanguard Capital Management, LLC 3.94%
Geode Capital Management, LLC 2.44%

Unit Economics (Per $1K Revenue)

★★★★★
KRMD generates approximately $623 of gross profit, $-72 of operating income, and $-11 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.84% (Tax Credit)

Quantitative Style Profile

★★★★★
KRMD has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Domestic CoreSales of FREEDOM60 and FreedomEdge syringe infusion drivers, HIgH-Flo safety needle sets, and precision flow rate tubing in the U.S.This is the primary engine of the company, generating recurring sales of disposable supplies every time patients perform treatments.
International CoreDistribution of infusion pumps and proprietary disposables across global markets via international partners and direct regulatory approvals.Provides a secondary geographic growth avenue as international adoption of subcutaneous therapy scales up.
Pharma Services and Clinical TrialsCollaborating with drug developers to evaluate and integrate infusion systems for clinical trials and novel drug co-formulations.Builds future growth pipelines by embedding KORU's technology directly into upcoming pharmaceutical drug labels.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-10
When After Market
Estimate -0.02
Actual 0.02

Profitability

Profit Margin -1.78%
Operating Margin (TTM) -1.25%

Management Effectiveness

Return on Assets (TTM) -1.29%
Return on Equity (TTM) -4.59%

Valuation

Trailing PE -
Forward PE 92.59
Enterprise Value 156.41M
Price to Sales(TTM) 3.47
Enterprise Value 156.41M
Price to Sales(TTM) 3.47
Enterprise Value to Revenue 3.38
Enterprise Value to EBITDA 786.59
Shares Outstanding 43.38M
Shares Floating 31.62M
Shares Outstanding 43.38M
Shares Floating 31.62M
Percent Insiders 8.77
Percent Institutions 58.59

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.